Table 3.

Adjusted hazard ratios of 5-year surgical complications after midurethral sling surgery, stratified by subgroups of age and diabetes mellitus.

	Available N	No. of events	HR (95% CI)
Age ≤ 65 years
Diabetes mellitus
No	1429	50	Ref
Yes	94	5	1.793 (0.669, 4.807)
Surgical duration (h)	1523	55	1.111 (0.912, 1.355)
Menopausal syndrome diagnosis
No	1389	45	Ref
Yes	134	10	2.222 (0.982, 5.029)
Hormone replacement therapy
No	1360	42	Ref
Yes	163	13	1.384 (0.596, 3.215)
Average flow rate (ml/s)	1423	55	0.929 (0.853, 1.012)
TVT-O sling type
TOT	475	12	Ref
TVT-O	885	32	1.235 (0.598, 2.547)
Age > 65 years
Diabetes mellitus
No	354	30	Ref
Yes	84	8	1.185 (0.476, 2.952)
Surgical duration (h)	438	38	0.966 (0.697, 1.338)
Menopausal syndrome diagnosis
No	378	33	Ref
Yes	60	5	0.618 (0.146, 2.618)
Hormone replacement therapy
No	316	21	Ref
Yes	122	17	2.131 (0.880, 5.163)
Average flow rate (ml/s)	423	35	1.036 (0.893, 1.201)
TVT-O sling type
TOT	145	7	Ref
TVT-O	253	23	1.392 (0.516, 3.754)
Diabetes mellitus
Age (year)	178	13	1.013 (0.959, 1.069)
Surgical duration (h)	178	13	1.630 (0.971, 2.735)
Menopausal syndrome diagnosis
No	162	12	Ref
Yes	16	1	0.000 (0.000, 0.000)
Hormone replacement therapy
No	143	10	Ref
Yes	35	3	0.340 (0.036, 3.207)
Average flow rate (ml/s)	170	12	1.049 (0.923, 1.193)
TVT-O sling type
TOT	83	4	Ref
TVT-O	87	8	1.249 (0.400, 3.895)
Non-diabetes mellitus
Age (year)	1783	80	1.015 (0.989, 1.041)
Surgical duration (h)	1783	80	1.023 (0.847, 1.235)
Menopausal syndrome diagnosis
No	1605	66	Ref
Yes	178	14	1.504 (0.743, 3.046)
Hormone replacement therapy
No	1533	53	Ref
Yes	250	27	2.239 (1.235, 4.057)*,a
Average flow rate (ml/s)	1676	78	0.940 (0.860, 1.028)
TVT-O sling type
TOT	537	15	Ref
TVT-O	1051	47	1.191 (0.611, 2.321)

CI, confidence interval; HR, hazard ratio; TOT, transobturator tape; TVT-O, tension-free vaginal tape-obturator.

*Statistically significant.

^aP for interaction with hormone replacement therapy was 0.0807.